Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sander Florman

Showing results (91-100 of 134) with videos related to

Pageof 14
Sort By:
Gastroenterology|July 31, 2021
Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) ConsortiumNeil Mehta, Catherine Frenette, Parissa Tabrizian, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 28, 2019
Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trialsBernd Schröppel, Enver Akalin, Mukta Baweja, et al.
Hepatology (Baltimore, Md.)|January 14, 2025
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort studyEdison Xu, Parissa Tabrizian, Julio Gutierrez, et al.
Clinical Transplantation|February 21, 2018
Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXTSander Florman, Flavio Vincenti, Antoine Durrbach, et al.
Transplantation|November 16, 2010
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studiesChristian P Larsen, Josep Grinyó, José Medina-Pestana, et al.
Transplantation Proceedings|November 2, 2025
Understanding Decision Making and Post-Donation Experiences for Robotic Single Port and Laparoscopic Donor NephrectomyDaniel Wang, Christopher Connors, Juan Sebastian Arroyave Villada, et al.
Annals of Surgical Oncology|February 9, 2024
Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes of an International AnalysisMatthew L Holzner, Vincenzo Mazzaferro, Michele Droz Dit Busset, et al.
The Lancet. HIV|July 31, 2020
Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational studyTania S Bonny, Charles Kirby, Craig Martens, et al.
Frontiers in Immunology|May 2, 2022
Differences in Humoral and Cellular Vaccine Responses to SARS-CoV-2 in Kidney and Liver Transplant RecipientsLucrezia Furian, Francesco Paolo Russo, Gianluigi Zaza, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 9, 2010
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United StatesElizabeth A Pomfret, Kenneth Washburn, Christoph Wald, et al.
Pageof 14

Showing results (91-100 of 134) with videos related to

Sort By:
Pageof 14
Gastroenterology|July 31, 2021
Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) ConsortiumNeil Mehta, Catherine Frenette, Parissa Tabrizian, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 28, 2019
Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trialsBernd Schröppel, Enver Akalin, Mukta Baweja, et al.
Hepatology (Baltimore, Md.)|January 14, 2025
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort studyEdison Xu, Parissa Tabrizian, Julio Gutierrez, et al.
Clinical Transplantation|February 21, 2018
Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXTSander Florman, Flavio Vincenti, Antoine Durrbach, et al.
Transplantation|November 16, 2010
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studiesChristian P Larsen, Josep Grinyó, José Medina-Pestana, et al.
Transplantation Proceedings|November 2, 2025
Understanding Decision Making and Post-Donation Experiences for Robotic Single Port and Laparoscopic Donor NephrectomyDaniel Wang, Christopher Connors, Juan Sebastian Arroyave Villada, et al.
Annals of Surgical Oncology|February 9, 2024
Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes of an International AnalysisMatthew L Holzner, Vincenzo Mazzaferro, Michele Droz Dit Busset, et al.
The Lancet. HIV|July 31, 2020
Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational studyTania S Bonny, Charles Kirby, Craig Martens, et al.
Frontiers in Immunology|May 2, 2022
Differences in Humoral and Cellular Vaccine Responses to SARS-CoV-2 in Kidney and Liver Transplant RecipientsLucrezia Furian, Francesco Paolo Russo, Gianluigi Zaza, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 9, 2010
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United StatesElizabeth A Pomfret, Kenneth Washburn, Christoph Wald, et al.
Pageof 14